Mira Pharmaceuticals Terminates $4.5 Million Securities Purchase Agreement

Mira Pharmaceuticals Inc. terminated its securities purchase agreement with an institutional investor on June 4, 2026, the company reported in an 8-K filing with the Securities and Exchange Commission.

The agreement, originally executed on April 2, 2025, provided for the investor to purchase up to $4.5 million of the company's common stock in a private placement. Under the original terms the investor received registration rights for the shares. The termination agreement, executed June 3, 2026, ends all future purchase obligations, cancels the investor's registration rights, and requires no further payments or deliveries by either party.

The termination affects the company's prior plan to raise up to $4.5 million in committed capital. No shares had been issued under the agreement prior to termination. Operationally, Mira no longer has a contractual path to that specific financing and the investor no longer holds any claim on future securities or registration assistance from the company.

The change took effect immediately upon execution of the termination agreement on June 3, 2026.

Downstream, the company must evaluate alternative financing options if it intends to replace the terminated capital. The filing triggers standard SEC disclosure obligations already satisfied by the 8-K. No further contractual milestones remain under the terminated agreement.

Mira must continue to meet all other public-company reporting deadlines, including quarterly filings, without the prior expectation of $4.5 million in committed proceeds.

This termination follows the company's April 2025 entry into the original securities purchase agreement. The 8-K filed June 4, 2026, includes the termination agreement as an exhibit and was submitted under Items 1.01, 7.01 and 9.01.